New drug combo tested for aggressive blood cancer
NCT ID NCT06692452
Summary
This study aimed to see if adding the drug tazemetostat to standard CHOP chemotherapy could be more effective for people newly diagnosed with certain types of T cell lymphoma. The trial planned to enroll about 24 adults and measure how well the combination worked to eliminate the cancer and control its progression. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.